Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
Sign Up to like & getrecommendations! Published in 2021 at "Vaccine"
DOI: 10.1016/j.vaccine.2021.04.061
Abstract: The Global Polio Eradication Initiative (GPEI) faces substantial challenges with managing outbreaks of serotype 2 circulating vaccine-derived polioviruses (cVDPV2s) in 2021. A full five years after the globally coordinated removal of serotype 2 oral poliovirus… read more here.
Keywords: response; opv2; oral poliovirus; outbreak response ... See more keywords
Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
Sign Up to like & getrecommendations! Published in 2018 at "Expert Review of Vaccines"
DOI: 10.1080/14760584.2018.1506333
Abstract: ABSTRACT Introduction: Ending all cases of poliomyelitis requires successful cessation of all oral poliovirus vaccine (OPV), but the Global Polio Eradication Initiative (GPEI) partners should consider the possibility of an OPV restart. Areas covered: We… read more here.
Keywords: poliovirus vaccine; polio; oral poliovirus; possibility ... See more keywords
Quantitative RT-PCR Assays for Quantification of Undesirable Mutants in the Novel Type 2 Oral Poliovirus Vaccine
Sign Up to like & getrecommendations! Published in 2022 at "Vaccines"
DOI: 10.3390/vaccines10091394
Abstract: Emergence of mutations is an inherent property of RNA viruses with several implications for their replication, pathogenesis, and evolutionary adaptation. Oral poliovirus vaccine (OPV), developed by Albert Sabin, is composed of live attenuated polioviruses of… read more here.
Keywords: qmosrt pcr; quantification; oral poliovirus; pcr ... See more keywords